Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jonathon D. S. Holt"'
Autor:
Susan H. Fox, Jonathon D. S. Holt, Patrick A. Howson, Elizabeth F. Brigham, Tom H. Johnston, Jack T. Nguyen, Michael Hill, Carl Brown, Jonathan M. Brotchie
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 367:373-381
Dyskinesia is a common motor complication associated with the use of levodopa to treat Parkinson's disease. Numerous animal studies in mice, rats, and nonhuman primates have demonstrated that the N-methyl-d-aspartate antagonist, amantadine, dose depe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2206803db7d0f8600b8e41da22d5b52d
https://doi.org/10.1124/jpet.118.247650
https://doi.org/10.1124/jpet.118.247650
Autor:
Jonathon D. S. Holt, Cynthia Woodsong
Publikováno v:
Advanced Drug Delivery Reviews. 92:146-154
This paper reviews key issues found to affect acceptability and preferences for vaginal products to prevent HIV infection or HIV and pregnancy. We focus on the interplay between the biological and physico-chemical aspects of formulation and the socia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d35e27ce3b4d65baf6ecdfa2c92e77b
https://doi.org/10.1016/j.addr.2015.02.004
https://doi.org/10.1016/j.addr.2015.02.004
Publikováno v:
Current Obstetrics and Gynecology Reports. 4:43-52
Multipurpose prevention technologies (MPTs) are pharmaceutical products being developed for multiple indications, primarily prevention of HIV, pregnancy, and/or sexually transmitted infections. MPT products could be a combination of multiple drugs co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1184201b0e470e25cca6dd0568fde971
https://doi.org/10.1007/s13669-014-0107-6
https://doi.org/10.1007/s13669-014-0107-6
Autor:
Ian Major, Brid Devlin, Andrew Brimer, Clare McCoy, Jonathon D. S. Holt, Diarmaid J. Murphy, Susan M. Fetherston, R. Karl Malcolm, Sandeep Kumar, Wendy Blanda, Peter Boyd
Publikováno v:
Boyd, P, Fetherston, S M, McCoy, C F, Major, I, Murphy, D J, Kumar, S, Holt, J, Brimer, A, Blanda, W, Devlin, B & Malcolm, R K 2016, ' Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel ', International Journal of Pharmaceutics, vol. 511, no. 1, pp. 619-629 . https://doi.org/10.1016/j.ijpharm.2016.07.051
A matrix-type silicone elastomer vaginal ring providing 28-day continuous release of dapivirine (DPV) ⿿ a lead candidate human immunodeficiency virus type 1 (HIV-1) microbicide compound ⿿ has recently demonstrated moderate levels of protection in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5724c1be40fb5bf0655cdf956fd3122f
https://pure.qub.ac.uk/en/publications/matrix-and-reservoirtype-multipurpose-vaginal-rings-for-controlled-release-of-dapivirine-and-levonorgestrel(1c672efb-3a3e-40dc-bd55-f59c37050f55).html
https://pure.qub.ac.uk/en/publications/matrix-and-reservoirtype-multipurpose-vaginal-rings-for-controlled-release-of-dapivirine-and-levonorgestrel(1c672efb-3a3e-40dc-bd55-f59c37050f55).html
Autor:
William Pendergast, Kwen-Jen Chang, Garrett J. Gross, Ke Wei, Scott J. O'Neill, Jonathon D. S. Holt, Peter J. Gengo, Michael. J. Watson
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 316:423-430
A novel delta-receptor selective compound, ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2, 5-dimethylpiperazin-1-ylmethyl)benzoic acid], was evaluated for activity on infarct size in a rat model of acute myocardial inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa3f750a3e67d899e4bcf6aea8f4ceb2
https://doi.org/10.1124/jpet.105.092742
https://doi.org/10.1124/jpet.105.092742
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides
Autor:
Jeremy Nuttall, Nicola Dias, Jonathon D. S. Holt, Lisa C. Rohan, Alex Muntendam, J D Holding, David Cameron, Peter Dreier, Freddy Oostebring
Publikováno v:
Antimicrobial agents and chemotherapy. 59(7)
When developing novel microbicide products for the prevention of HIV infection, the preclinical safety program must evaluate not only the active pharmaceutical ingredient but also the product itself. To that end, we applied several relatively standar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3e3f7d54a9e9961496f7b327ed68a52
https://pubmed.ncbi.nlm.nih.gov/25845860
https://pubmed.ncbi.nlm.nih.gov/25845860
Autor:
Jonathon D S, Holt, Jeremy P, Nuttall
Publikováno v:
Current topics in microbiology and immunology. 383
Before pharmaceutical products are evaluated in humans, it is essential that they undergo a rigorous safety assessment using in vitro models and studies in preclinical species. Once products progress into the clinic, additional preclinical studies ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8a554c34aab42f8a3899844def64995f
https://pubmed.ncbi.nlm.nih.gov/23612993
https://pubmed.ncbi.nlm.nih.gov/23612993
Autor:
Jonathon D. S. Holt, Jeremy Nuttall
Publikováno v:
Current Topics in Microbiology and Immunology ISBN: 9783662445952
Before pharmaceutical products are evaluated in humans, it is essential that they undergo a rigorous safety assessment using in vitro models and studies in preclinical species. Once products progress into the clinic, additional preclinical studies ar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b7ae2e709490eca2d1b12d6b03873f7
https://doi.org/10.1007/82_2013_327
https://doi.org/10.1007/82_2013_327
Autor:
Clare McCoy, Chris Gimour, Jonathon D. S. Holt, Jeremy Nuttall, Diarmaid J. Murphy, Wendy Blanda, Ian Major, Andrew Brimer, Tiffany Derrick, Brid Devlin, Peter Boyd, Karl Malcolm, Susan M. Fetherston
Publikováno v:
AIDS Research and Human Retroviruses. 30:A68-A68
Background: By extending the use duration of vaginal rings (VRs) the overall production cost per patient per month can be greatly reduced. Matrix-type ring designs produce an initial burst of drug release and concentrations during the burst must be m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0121146545e42ddf55b4b6e671121671
https://doi.org/10.1089/aid.2014.5124.abstract
https://doi.org/10.1089/aid.2014.5124.abstract